BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12934758)

  • 1. The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study.
    Stojanovic ND; Kwong P; Byrne DJ; Arnold A; Jagroop IA; Nair D; Press M; Hurel S; Mikhailidis DP; Prelevic GM
    Angiology; 2003; 54(4):391-9. PubMed ID: 12934758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycaemic control and plasma lipoproteins in menopausal women with Type 2 diabetes treated with oral and transdermal combined hormone replacement therapy.
    Darko DA; Dornhorst A; Kennedy G; Mandeno RC; Seed M
    Diabetes Res Clin Pract; 2001 Dec; 54(3):157-64. PubMed ID: 11689270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of transdermal and oral estrogen replacement on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus.
    Araújo DA; Farias ML; Andrade AT
    Climacteric; 2002 Sep; 5(3):286-92. PubMed ID: 12419087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Plasma levels of total cholesterol, LDL-cholesterol, and HDL-cholesterol in postmenopausal women during 12 months' oral administration of dydrogesterone or medroxyprogesterone combined with continuous transdermal supplementation of 17beta-estradiol].
    Milewicz T; Kostecka A; Rogatko I; Sztefko K; Kwiatkowska-Panek E; Radowick S; Krzysiek J
    Przegl Lek; 2007; 64(2):65-9. PubMed ID: 17892034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion.
    Cucinelli F; Paparella P; Soranna L; Barini A; Cinque B; Mancuso S; Lanzone A
    Eur J Endocrinol; 1999 Mar; 140(3):215-23. PubMed ID: 10216516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 2-year study on the beneficial effects of 17 beta-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone.
    van der Mooren MJ; Demacker PN; Thomas CM; Borm GF; Rolland R
    Eur J Obstet Gynecol Reprod Biol; 1993 Dec; 52(2):117-23. PubMed ID: 8157140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels.
    Chiantera V; Sarti CD; Fornaro F; Farzati A; De Franciscis P; Sepe E; Borrelli AL; Colacurci N
    Menopause; 2003; 10(4):286-91. PubMed ID: 12851511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hormone replacement therapy on insulin secretion and insulin sensitivity in postmenopausal diabetic women.
    Borissova AM; Tankova T; Kamenova P; Dakovska L; Kovacheva R; Kirilov G; Genov N; Milcheva B; Koev D
    Gynecol Endocrinol; 2002 Feb; 16(1):67-74. PubMed ID: 11915585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hormone replacement therapy with 17 beta-estradiol dydrogesterone: results of a 3-month open-label study].
    Grisar J; Travica S; Metka M; Pietschmann P
    Wien Klin Wochenschr; 1999 Dec; 111(24):1035-43. PubMed ID: 10677891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of hormonal replacement therapy on chromium status and glucose and lipid metabolism in postmenopausal women.
    Roussel AM; Bureau I; Favier M; Polansky MM; Bryden NA; Anderson RA
    Maturitas; 2002 May; 42(1):63-9. PubMed ID: 12020981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women.
    Prelevic GM; Kwong P; Byrne DJ; Jagroop IA; Ginsburg J; Mikhailidis DP
    Fertil Steril; 2002 May; 77(5):945-51. PubMed ID: 12009348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risk factors during sequentially combined 17 beta oestradiol and dydrogesterone (Femoston); results from a one-year study in postmenopausal women.
    Gelfand M; Fugère P; Bissonnette F
    Maturitas; 1997 Mar; 26(2):125-32. PubMed ID: 9089562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women.
    Foster RH; Balfour JA
    Drugs Aging; 1997 Oct; 11(4):309-32. PubMed ID: 9342560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral versus transdermal hormone replacement therapy.
    Stevenson JC; Crook D; Godsland IF; Lees B; Whitehead MI
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 1():30-5. PubMed ID: 8499957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ultra-low-dose estradiol and dydrogesterone on arterial stiffness in postmenopausal women.
    Matsui S; Yasui T; Tani A; Kato T; Uemura H; Kuwahara A; Matsuzaki T; Arisawa K; Irahara M
    Climacteric; 2014 Apr; 17(2):191-6. PubMed ID: 24164272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
    Stephenson K; Neuenschwander PF; Kurdowska AK
    Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin sensitivity during postmenopausal hormone replacement with transdermal estradiol and intrauterine levonorgestrel.
    Raudaskoski T; Tomás C; Laatikainen T
    Acta Obstet Gynecol Scand; 1999 Jul; 78(6):540-5. PubMed ID: 10376866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral 17beta-estradiol (1 mg) continuously combined with dydrogesterone improves the serum lipid profile of postmenopausal women.
    Pornel B; Chevallier O; Netelenbos JC
    Menopause; 2002; 9(3):171-8. PubMed ID: 11973440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women.
    Godsland IF; Manassiev NA; Felton CV; Proudler AJ; Crook D; Whitehead MI; Stevenson JC
    Clin Endocrinol (Oxf); 2004 May; 60(5):541-9. PubMed ID: 15104556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National differences in lipid response to postmenopausal hormone replacement therapy.
    Ranta V; Oksanen H; Arrenbrecht S; Ylikorkala O
    Maturitas; 2002 Aug; 42(4):259-65. PubMed ID: 12191848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.